TenQ

The Sarepta Therapeutics story

Sarepta Therapeutics develops genetic medicines for rare diseases, with the central question whether its Duchenne products can fund a broader pipeline after ELEVIDYS lost access to non-ambulatory patients.

Sarepta Therapeutics stock reportTenQ Score 12/36 · every chart and check from its filings
  • $17.10share price, last close
  • $1.8Bmarket value
  • 12/36TenQ Score checks passed

The story in brief

  • PMOs anchor revenue. In the quarter to June 2026, PMO products generated $230.6 million of Sarepta's $328.7 million in net product revenues, while ELEVIDYS contributed $98.1 million.
  • Cost reductions matter. Sarepta achieved $13.3 million in GAAP operating income in the quarter to June 2026 as restructuring reduced research, manufacturing and personnel expenses.
  • Approval questions remain. FDA acceptance of the AMONDYS 45 and VYONDYS 53 applications advances their review for traditional approval, but does not resolve the uncertainty following ESSENCE's missed primary endpoint.

What drives the business

  • Sarepta's commercial foundation is Duchenne muscular dystrophy treatment through its exon-skipping PMO products, EXONDYS 51, VYONDYS 53 and AMONDYS 45, and its gene therapy ELEVIDYS.
  • Sarepta retains U.S. rights to ELEVIDYS, while Roche holds an exclusive license to develop, manufacture and commercialize it outside the U.S., making Roche both a commercialization partner and a recipient of Sarepta's contract manufacturing supply.
  • The Arrowhead collaboration expands Sarepta into siRNA medicines for diseases including DM1 and FSHD, following a $500.0 million upfront cash payment and $300.0 million in achieved and settled enrollment-related payments.
  • The July 2025 restructuring narrowed development priorities and reduced expenses, with research and development spending falling to $91.3 million in the quarter to June 2026 from $204.4 million in the comparable period of 2025.
  • Revenue includes more than product demand: the six months to June 2026 included $365.0 million of collaboration revenue associated with Roche's declined option for certain program rights and the first commercial ELEVIDYS dosing milestone in Japan.

What the price assumes

A growth assumption at $17.53 is not measurable because the reverse DCF's negative cash flow premise conflicts with positive free cash flow of $82 million over the last twelve months.

The price represents 0.9x sales and a 4.4% free cash flow yield, exceeding the TenQ cash yield check's 3.0% bar, but the check comparing implied growth with Sarepta's record remains unresolved because of losses.

Revenue growth over the last twelve months was -20.4%, against an annual growth pace of 33.1% over the last three years, while the operating margin was -7.3%.

What could change the story

  • ELEVIDYS received a boxed warning for acute liver injury and acute liver failure in November 2025, and resuming treatment of non-ambulatory patients depends on FDA review of the sirolimus study and agreement on a revised label.
  • ESSENCE did not reach statistical significance on its primary endpoint, leaving uncertainty around traditional approval for AMONDYS 45 and VYONDYS 53 despite FDA acceptance of their applications.
  • New U.S. healthcare pricing policies and tariffs on imported patented pharmaceuticals could reduce coverage and pricing, while changing foreign approval requirements could delay access outside the U.S.
  • TenQ's interest coverage check fails, and stock-based pay of $99 million exceeded free cash flow of $82 million over the last twelve months, underscoring financing and dilution pressures despite positive cash generation.
  • Sarepta recorded a $39.0 million patent litigation contingency charge in the quarter to June 2026 and entered a settlement agreement with REGENXBIO, the University of Pennsylvania and Catalent in September 2026, making subsequent accounting and payment disclosures relevant to liquidity.

What to watch next

  • The August 2026 outlook narrowed net product revenue guidance for 2026 to $1.2-$1.3 billion and combined non-GAAP R&D and SG&A expense guidance to $800.0-$850.0 million, with PMO revenue, ELEVIDYS revenue and operating income showing whether the reduced cost base supports profitability.
  • The next regulatory updates should clarify the review of AMONDYS 45 and VYONDYS 53 for conversion from accelerated to traditional approval.
  • Sarepta expects phase 1/2 study readouts in DM1 and FSHD in the second half of 2026, providing evidence about the Arrowhead pipeline's clinical progress.
  • Sarepta expects full enrollment of ENDEAVOR Cohort 8 by the end of 2026 and 12-week results from the full cohort in the first quarter of 2027, relevant to the potential path back to ELEVIDYS dosing in non-ambulatory patients.

Sources

Back to the SRPT report